Abstract
Levetiracetam is an antiepileptic drug (AED) with a favourable tolerability profile with little or no effect on liver function. We describe an epileptic patient who developed a significant increase in gamma glutamyltransferase (γGT) while on levetiracetam monotherapy.
Article PDF
Similar content being viewed by others
References
Bilo L, Meo R, de Leva MF, et al. Levetiracetam in patients with epilepsy and chronic liver disease: observations in a case series. Clin Neuropharmacol 2008; 31: 221–225.
Carreno M. Levetiracetam. Drugs Today (Barc) 2007; 43: 769–794.
Chabolla DR, Harnois DM, Meschia JF. Levetiracetam monotherapy for liver transplant patients with seizures. Transplant Proc 2003; 35: 1480–1481.
Glass GA, Stankiewicz J, Mithoefer A, et al. Levetiracetam for seizures after liver transplantation. Neurology 2005; 64: 1084–1085.
Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 2003; 25: 123–129.
Tan TC, de Boer BW, Mitchell A, et al. Levetiracetam as a possible cause of fulminant liver failure. Neurology 2008; 71: 685–686.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Broli, M., Provini, F., Naldi, I. et al. Unexpected gamma glutamyltransferase rise increase during levetiracetam monotherapy. Epileptic Disord 12, 81–82 (2010). https://doi.org/10.1684/epd.2010.0291
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/epd.2010.0291